Ivoclar Vivadent AG Overview
Ivoclar is one of the world's largest independent, family-owned dental materials and equipment companies, headquartered in Schaan, Liechtenstein, with more than a century of history. Its franchise is built on aesthetic restorative materials, above all the IPS e.max lithium disilicate glass-ceramic system launched in 2005, which the company states has been used in more than 230 million restorations worldwide, together with denture teeth (the company's original business), composites and adhesives for dentists, and ceramic furnaces (the Programat series, in which it claims global leadership). Ivoclar sells an integrated "materials + equipment + workflow + education" proposition to two core customer groups, dentists and dental laboratories, plus preventive-care teams. With roughly CHF 0.85 to 0.87 billion in annual turnover (FY2021 to FY2023), approximately 3,600 staff, five production sites and 71 education centres, it is a mid-sized premium player positioned between diversified US-listed dental conglomerates and smaller European specialists, and it is currently executing a cost-and-focus programme alongside a "Local4Local" regional-production strategy.
What the company does
Ivoclar develops, manufactures and markets dental materials, dental equipment, and related software/workflow integrations for dental practices and dental laboratories. The company frames its offer as "integrated solutions" across the treatment process, organised (per its public materials and Wikipedia) into four product areas:
-
Direct Restoratives: composites (Tetric family), adhesives (Adhese, Adhese Universal / Adhese 2), curing lights (Bluephase), isolation devices (OptraGate, OptraDam), and preventive/care products (Cervitec, Fluor Protector, Proxyt and others under "Prevention & Care").
-
Fixed Prosthetics: all-ceramic systems (IPS e.max Press, CAD, ZirCAD, Ceram, Ceram Art; IPS e.max Zirconia launched 2026), luting cements (Variolink, Multilink, SpeedCEM), ceramic furnaces (Programat), and legacy press-ceramic technology (IPS Empress, introduced 1991).
-
Removable Prosthetics: denture teeth (SR Phonares and other SR lines), denture base materials (Ivobase), and the Ivotion digital denture system (monolithic denture milled from a single disc).
-
Digital Dentistry: CAD/CAM milling machines (PrograMill series, including PrograMill 7 and 7 Pure launched May 2026), CAM software, validated partner workflows with 3Shape, exocad, vhf and SprintRay, and AR-based patient consultation software (from the Kapanu acquisition).
The company's own description
In its standard media boilerplate (2023 to 2026 releases), the company describes the Ivoclar Group as one of the world's leading manufacturers of integrated solutions for high-quality dental applications, built on a comprehensive portfolio of products, systems and services, strong research and development, and a commitment to education. Its stated mission is "Making People Smile." The corporate "About Us" page states that it serves dentists, dental technicians and dental hygienists, and characterises disruptive innovation as part of its DNA. No annual report is published, so there is no formal annual-report business description.
Business model and revenue model
| Revenue stream | Nature | Disclosure |
|---|---|---|
| Consumable materials (ceramics, composites, adhesives, cements, denture teeth, prophylaxis) | Recurring, replenishment-driven product sales | Split not disclosed; widely regarded as the bulk of revenue |
| Equipment (furnaces, milling machines, curing lights) | Capital goods with installed-base pull-through of consumables | Split not disclosed |
| Software / digital | CAM software, updates, AR consultation apps; largely bundled | Not disclosed; no subscription revenue line reported |
| Services | Repair, customer care (e.g. São Paulo repair centre), training via Ivoclar Academy | — |
| Licensing | Material/workflow validation programmes with machine makers (e.g. "Authorized Milling Partner") | Commercial terms not disclosed |
Independent characterisation. Ivoclar's economics resemble a "razor/razor-blade" materials franchise: equipment (Programat furnaces, PrograMill mills) and validated workflows lock laboratories and practices into proprietary consumables (IPS e.max blocks, ingots and discs). Its competitive moat is the IPS e.max brand plus clinical evidence (a company scientific report in December 2025 cited survival rates above 95%), extensive education infrastructure, and a strong dealer and laboratory channel. Revenue is product-based; there is no disclosed subscription or licensing line of material size.
Value-chain position
Ivoclar sits in upstream manufacturing and R&D, selling principally through dental distributors/dealers (e.g. full-service dental dealers in Europe and North America) and directly to large laboratories, with its own subsidiaries handling marketing, education and technical support. It does not operate clinics or laboratories itself. It is increasingly building downstream logistics (global distribution centre in Ellwangen, Germany; automated US warehouse in Amherst, New York; Leicester, UK; São Paulo, Brazil).
Customer types and end-markets
| Customer type | Products | Notes |
|---|---|---|
| Dentists (general and aesthetic practices) | Direct restoratives, adhesives, cements, chairside CAD/CAM blocks, curing lights, isolation | The "dentist business" grew 39.2% in FY2021 (company release) |
| Dental laboratories / technicians | Ceramics, furnaces, mills, denture teeth, Ivotion | Lab business grew 23.1% in FY2021, driven by digital solutions |
| Dental hygienists / prevention teams | Prevention & Care portfolio | Separate IDS 2025 stand for Prevention & Care |
| Implant/full-arch clinicians | Zirconia and implant-supported restorative concepts | MALO CLINIC partnership (2025) targets All-on-4 workflows |
| Dental schools / students | Education | Ivoclar Summer School (since 2022); approx. 160 students from 31 countries in 2026 |
Strategy
Stated strategic themes (paraphrased from company releases; no annual report or investor day exists)
-
Focus on core competencies and strategic priorities (March 2024 reorganisation): sharpen portfolio, cut costs, reduce workforce.
-
Growth markets emphasis (Heinz's 2023 mandate): increased focus on growth markets and core products, while investing in future innovation.
-
Local4Local (since 2023): move production and logistics closer to markets for supply-chain resilience, regulatory fit and customer proximity.
-
Integrated end-to-end workflows and open digital ecosystem: validated partner machines and software rather than a closed proprietary stack.
-
Education as a moat: Ivoclar Academy, 71 centres, Summer School, Media Connect (first edition 14 April 2026).
-
Customer centricity: IDS 2025 messaging put customers at the centre.
Initiatives in the last 24 months (Oct 2024 to Oct 2026)
| Initiative | Date | Type | Detail |
|---|---|---|---|
| IDS 2025 dual presence | Mar 2025 | Commercial | Separate main and Prevention & Care stands |
| MALO CLINIC partnership | 2,025 | Partnership | All-on-4 / implant-supported restorative concepts; joint studies with IPS e.max zirconia |
| vhf validation expansion | Nov 2025 | Ecosystem | Z4 and E4 machines validated for IPS e.max CAD; starter-package vouchers for practices |
| Marketing leadership rebuild | Jul 2025 | Organisation | CMO appointed |
| IPS e.max 20-year campaign | Sep to Nov 2025 | Brand | Events in Leipzig and Vienna |
| Scientific Report Vol. 4 | Dec 2025 | Evidence | e.max survival rates above 95% |
| IPS e.max Ceram Art | Dec 2025 | Product | Stain/glaze/structure paste line |
| Ivoclar Smile Award | Jan 2026 | Brand | Global case award for IPS e.max |
| OptraGate Dry Control; Adhese 2 | Mar 2026 | Product | Direct restorative upgrades |
| Ivoclar Media Connect | Apr 2026 | Communications | First media event at the new campus |
| Shanghai production LOI | Apr 2026 (announced Jun 2026) | Footprint | Production from 2028 |
| IPS e.max Zirconia; PrograMill 7 / 7 Pure | May 2026 | Product | Fast-fire zirconia; new mill generation |
| New gingiva and tooth shades | Jul 2026 | Product | Personalised dentures |
| Anti-counterfeiting campaign | Jul 2026 | Brand protection | Action against counterfeit goods and unsafe trading channels |
| Amherst warehouse automation | 2026 (ongoing) | Logistics | Conversion to automated warehouse |
| "Simplify Your Filling Therapy" | Sep 2026 | Workflow | Direct-restorative simplification |
Cost programme
| Programme | Announced | Scope | Target |
|---|---|---|---|
| Reorganisation and cost reduction | 4 Mar 2024 | Workforce reductions at several locations; approx. 240 employees affected globally; redundancy (social) plan in place | Savings target not disclosed |
Sustainability/ESG commitments
No quantified public targets were located.
Medium-term financial targets / guidance
None publicly disclosed. The company has never published margin or growth targets. Its last outlook statement located (March 2022) described it as cautiously optimistic given geopolitical uncertainty.
Products & Services
Pricing models are not publicly disclosed by the company at group level; products are sold through dealers at list prices that vary by country. Launch years are given where verified; otherwise marked.
Fixed Prosthetics / All-Ceramics
| Product | Description & key capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| IPS e.max (system) | Lithium disilicate glass-ceramic family for crowns, veneers, inlays/onlays, bridges; company reports more than 230 million restorations (sales-based) | Labs, dentists | 2005; 20th anniversary 2025 | Flagship franchise; Dec 2025 scientific report (Vol. 4) cites survival rates above 95% |
| IPS e.max CAD | Machinable lithium disilicate blocks ("blue blocks"), patented; indication range expanded at IDS 2013 | Chairside dentists, labs | 2005 introduction; expanded 2013 | Authorised milling partners: vhf N4+ (2024), Z4 and E4 (2025) |
| IPS e.max Press | Pressable ingots | Labs | Press tech since 1991 (Empress) | 30 years of press technology celebrated (2021) |
| IPS e.max ZirCAD (incl. Prime, Prime Esthetic) | Zirconia discs; Prime Esthetic launched 2021 | Labs | 2021 (Prime Esthetic) | Updated features presented 2024 |
| IPS e.max Zirconia | New zirconia addition to the e.max family, developed with technicians; multiple fast-fire protocols | Labs | May 2026 | Planned use in MALO CLINIC implant studies |
| IPS e.max Ceram | Veneering ceramic | Labs | — | Gingiva shades promoted 2025 |
| IPS e.max Ceram Art | Ready-to-use stain, glaze and structure pastes for monolithic, pressed and layered restorations | Labs | Dec 2025 | Showcased at LMT Lab Day West 2026 |
| IPS Empress | Leucite-reinforced press ceramic (first press ceramic) | Labs, dentists | 1,991 | Legacy line |
| Programat furnaces (e.g. P-series, CS-series) | Press and firing furnaces; company claims global market leadership | Labs, chairside | Ongoing (CS6 referenced) | Installed-base anchor for consumables |
| Luting cements: Variolink, Multilink, SpeedCEM | Adhesive and self-adhesive resin cements | Dentists | — | Completes the ceramic workflow |
Direct Restoratives and Prevention & Care
| Product | Description | Target customer | Launch / latest |
|---|---|---|---|
| Tetric family (incl. Tetric plus) | Composite restoratives; 2025 YouTube "Smart proof" series promotes shrinkage behaviour of Tetric plus | Dentists | Tetric plus: c.2025 |
| Adhese 2 | Latest adhesive; dual-polymerisation capability for the VivaPen | Dentists | Mar 2026 |
| Bluephase | LED curing lights | Dentists | — |
| OptraGate / OptraGate Dry Control | Lip and cheek retractor; moisture control and access | Dentists | Dry Control: Mar 2026 |
| "Simplify Your Filling Therapy" workflow | Integrated direct-filling workflow (company promotes "4 instead of 3 treatments" efficiency) | Dentists | Sep 2026 |
| Prevention & Care range (e.g. Cervitec, Fluor Protector, Proxyt) | Varnishes, prophy pastes | Hygienists | Ongoing; dedicated IDS 2025 stand |
Removable Prosthetics
| Product | Description | Target customer | Launch / latest |
|---|---|---|---|
| Ivotion Denture System | Digital monolithic denture milled from one disc in a single uninterrupted process; design in 3Shape or exocad; ACP product innovation award Nov 2020 | Labs | c.2019 to 2020 |
| Denture teeth (SR lines, e.g. Phonares) | Premium denture teeth, the company's founding business | Labs | Ongoing |
| New gingiva and tooth shades | Extended shades for personalised prostheses | Labs | Jul 2026 |
| Ivobase | Denture base system | Labs | — |
Digital Dentistry
| Product | Description | Target customer | Launch / latest |
|---|---|---|---|
| PrograMill 7 | Five-axis mill; 1.5 kW spindle for IPS e.max CAD and titanium alloys; automatic wet/dry changeover without manual cleaning; 12-inch display | Labs | May 2026 |
| PrograMill 7 Pure | Compact variant for in-house labs and clinics | In-house labs, clinics | May 2026 |
| Earlier PrograMill (One, PM3, PM5, PM7) | Prior generation mills launched under "Ivoclar Digital" | Labs, chairside | From 2017 |
| PrograMill CAM software | Material-specific milling strategies | Labs | Ongoing |
| AR consultation app (Kapanu tech) | Real-time 3D preview of treatment result | Dentists | 2,019 |
| Partner workflows | 3Shape, exocad, vhf, SprintRay, Cayster | Labs, dentists | 2020 to 2025 |
Services
| Service | Description |
|---|---|
| Ivoclar Academy | Online platform (webinars, studies, virtual workshops) launched in the COVID period |
| ICDE / education centres | 71 centres worldwide; flagship in Schaan; e.g. Canada centre opened 2012 |
| Ivoclar Summer School | Annual student programme since 2022; 2026 held in ten countries; approx. 160 students from 31 countries |
| LAB. EVOLUTION. LIVE. Tour 2026 | Mobile digital-lab van touring Germany/Austria |
| Repair & customer care | e.g. São Paulo repair centre (2024) |
Financial Narrative
Disclosure reality
Ivoclar publishes only a single headline turnover figure (and sometimes headcount and regional growth rates) via an annual press release. Gross profit, EBIT, EBITDA, net income, EPS, dividends, balance-sheet and cash-flow data are not publicly disclosed. The last turnover release located is for FY2023 (published 4 March 2024). No FY2024 or FY2025 turnover was found in company releases, trade press or Liechtenstein media as of 7 October 2026.
Income statement (5-year)
Notes: FY2021 growth in CHF computed against the disclosed FY2020 turnover of CHF 640 million (842/640 minus 1 = 31.6%); the company's own currency-adjusted figure is 31.2%. FY2022 and FY2023 CHF growth rates are simple arithmetic on reported figures. FY2023 currency-adjusted growth was positive in all regions per the company, but no percentage was given.
Long-run turnover history (all disclosed data points)
Sources: ZWP/IDS Today 2013 (FY2012); Dental Community Mar 2015 (FY2014); Dental Community 2018 (FY2017); liechtenstein.li Mar 2019 (FY2018); liechtenstein.li Mar 2021 (FY2020); Ivoclar Mar 2022 (FY2021); Ivoclar/Dentistry Today Mar 2023 (FY2022); Ivoclar Mar 2024 (FY2023). FY2019 turnover was described as a then-record but an exact figure was not located; FY2013, FY2015 and FY2016 not located.
Commentary. Reported CHF turnover has been essentially flat in the CHF 810 to 870 million band since 2017, except for the 2020 COVID trough. The flatness masks positive local-currency growth: the company repeatedly reports currency-adjusted growth above market (e.g. +4.9% in FY2022) but strong-franc translation erodes it, as explicitly stated in the FY2023 release (sales increases in all regions, yet CHF revenue below prior year). The inflection to watch is FY2024 onward: the company announced a restructuring in March 2024 citing currency, geopolitics and disproportionate cost increases, and then stopped publishing turnover. Silence after a long tradition of annual releases is itself a data point; it is consistent with a period of flat-to-lower CHF revenue, but this cannot be verified and is flagged as interpretation only.
Cash flow
The only disclosed investment figure located: a planned global investment of approx. CHF 82 million for 2018, of which CHF 39 million at Schaan (FY2017 release). Visible capital projects since then (new Schaan HQ building opened 2023; Ellwangen distribution centre 2021; Leicester 2023; São Paulo 2024; Amherst automation ongoing; Shanghai plant from 2028) indicate sustained capex, but amounts are not disclosed.
Productivity proxy (computed from disclosed figures only)
Note: FY2023 uses the approx. 3,800 FTE figure from the March 2024 release; other company statements from the same period cite approx. 3,700, which would imply approx. CHF 231 thousand. The broadly flat revenue-per-employee ratio since 2017 underlines why management targeted cost and headcount in 2024.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Area Details
| Product area | Contents |
|---|---|
Direct Restoratives | Composites, adhesives, curing lights, isolation, prevention & care |
Fixed Prosthetics | All-ceramics, zirconia, cements, furnaces |
Removable Prosthetics | Denture teeth, base materials, Ivotion |
Digital Dentistry | Mills, CAM software, partner workflows, AR |
Business (growth %, FY2021 vs FY2020, currency-adjusted where stated)
| Business (growth %, FY2021 vs FY2020, currency-adjusted where stated) | FY2021 |
|---|---|
Dentist business growth (%) | 39.2 |
Laboratory business growth (%) | 23.1 |
Group growth vs prior year (%) | 31.2 |
Segment (CHF Mn) Overview
| Segment (CHF Mn) | FY2023 |
|---|---|
Group turnover (CHF Mn) | 856 |
Revenue History
| Period | Sales structure | Source |
|---|---|---|
Mar 2023 | Christian Brutzer (CCO) responsible for the sales organisation of all markets | Dentistry Today (Mar 2023) |
From 1 Jan 2024 | Split into Mature Markets (Brutzer) and High Growth Markets (Mirco Stiehle: LATAM + APAC) | Ivoclar (Sep 2023) |
2025 to 2026 (current website) | CCO North America (Chester Spivey) and CCO LATAM & APAC (Mirco Stiehle) listed in corporate management; no CCO Mature Markets listed | ivoclar.com About Us |
Group Entities
| Entity | Country | Role |
|---|---|---|
Ivoclar Vivadent AG | Liechtenstein | Parent, HQ, R&D, production |
Ivoclar Vivadent GmbH | Germany (Ellwangen) | Sales subsidiary; global distribution centre |
Ivoclar Vivadent, Inc. / Ivoclar Inc. | USA (Amherst, NY) | North American subsidiary |
Wieland Dental + Technik / Wieland Dental Ceramics | Germany (Pforzheim) | Acquired 2012/13 (current status not disclosed) |
Kapanu AG | Switzerland | AR software, acquired 2017 (current status not disclosed) |
Manufacturing entities | Austria (Bürs), Italy (Naturns), Philippines (Manila), USA (Somerset NJ) | Production |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Revenue (CHF Mn) | 842 | 872 | 856 |
Revenue growth reported in CHF (%) | 31.6 | 3.6 | -1.8 |
Revenue growth currency-adjusted, company (%) | 31.2 | 4.9 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials
| Metric | FY2012 | FY2014 | FY2017 | FY2018 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
Group turnover (CHF Mn) | 658 | 761 | 809 | 810 | 640 | 842 | 872 | 856 |
Valuation Snapshot
| Metric | Value |
|---|---|
CAGR FY2012 to FY2023 (11 years, CHF) | approx. 2.4% |
CAGR FY2017 to FY2023 (6 years, CHF) | approx. 0.9% |
CAGR FY2021 to FY2023 (2 years, CHF) | approx. 0.8% |
Key Financials (FY2017–FY2023)
| Metric | FY2017 | FY2021 | FY2023 |
|---|---|---|---|
Turnover (CHF Mn) | 809 | 842 | 856 |
Employees (year-end headcount or FTE as disclosed) | 3,596 | 3,548 | 3,800 |
Turnover per employee (CHF K) | 225 | 237 | 225 |
Region growth (%)
| Region growth (%) | FY2014 | FY2017 | FY2021 |
|---|---|---|---|
Europe / EMEA growth (%) | 3.4 | 1.5 | 31.0 |
North America growth (%) | 1.4 | 3.9 | 36.0 |
Latin America growth (%) | 14.5 | 14.7 | 61.3 |
Asia Pacific growth (%) | 5.6 | 9.7 | 17.2 |
Orient & Africa growth (%) | 27.0 | — | — |
Group growth, local currency (%) | 4.4 | 3.3 | 31.2 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (no listed shares) |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable / not publicly disclosed |
Peer multiples | Not computed here (Ivoclar has no market value to compare) |
Analyst consensus | None (no sell-side coverage) |
Dividend history and policy | Not publicly disclosed (distributions to family owners, if any, are private) |
Credit ratings (Moody's, S&P, Fitch) | None located; no public bonds identified |
Public debt instruments | None identified |
Analyst Conclusions
Management guidance
No numeric guidance is published. Qualitative direction from 2023 to 2026 releases: focus on core products and growth markets, cost discipline after the 2024 reorganisation, regionalised production (Local4Local), continued product-led innovation (e.max Zirconia, PrograMill 7), and education-driven customer intimacy.
Consensus growth expectations
None exist (no analyst coverage). Industry context: digital dentistry projected at approx. 9.6% CAGR to 2031 (Mordor Intelligence, 2026).
Bull case
-
e.max into zirconia: extending the strongest brand in all-ceramics into fast-fire zirconia (May 2026) can recapture share lost to low-cost monolithic zirconia.
-
Leaner cost base: headcount down from approx. 3,700 to 3,800 (2023) to approx. 3,600 (2026) after the 2024 programme should lift margins if local-currency growth resumes.
-
Footprint and channel investments maturing: Ellwangen, Leicester, São Paulo, Amherst automation and Shanghai (2028) should improve service levels, tariff resilience and access to the high-growth markets that historically grew fastest.
Bear case
-
Structural CHF stagnation: reported revenue has barely moved since 2017 (approx. 0.9% CAGR to 2023), and disclosure stopped thereafter.
-
Commoditisation: generic lithium disilicate, Chinese zirconia and counterfeits erode price premiums on the core franchise.
-
Sub-scale in digital: without owning scanners, CAD or printers, Ivoclar depends on partners whose ecosystems may favour rival materials, while larger peers bundle implants, scanners and consumables.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Any FY2025/FY2026 turnover disclosure (typically March) | Resumption would signal confidence; continued silence would reinforce caution |
| IDS 2027 (Cologne, March 2027) preparations and launches | Primary launch platform |
| Adoption of IPS e.max Zirconia and PrograMill 7 in US/EU labs | Tests the zirconia extension thesis |
| Shanghai site progress (permits, construction) | Execution of Local4Local |
| Further management or board changes | Stability after several transitions |
| Additional production consolidation in Europe | Margin vs disruption trade-off |
| MALO CLINIC study outputs | Credibility in implant-restorative space |
| CHF exchange rate vs EUR/USD | Largest single swing factor for reported revenue |
| Counterfeit enforcement outcomes | Brand integrity |
Analyst verdict
Ivoclar is a high-quality, innovation-rich but financially opaque dental materials company whose investment case, for any counterparty (supplier, distributor, partner, acquirer or competitor), rests on the durability of the IPS e.max franchise and its ability to convert a century of materials science into relevance in a digitising, increasingly commoditised market. The verifiable record is mixed. On one side, the company owns arguably the best-known brand in all-ceramic dentistry, a claimed leadership position in ceramic furnaces, more than 240 R&D staff, 71 education centres, and a demonstrated ability to rebound from shocks (COVID trough of CHF 640 million in 2020 to a record CHF 872 million in 2022). On the other side, reported CHF turnover has been effectively flat for six years, revenue per employee has not improved since 2017, the company needed a restructuring in 2024 affecting roughly 240 roles, leadership has turned over repeatedly since 2019, and it has stopped publishing even headline turnover after FY2023.
Management's response is coherent: protect the core by extending e.max into zirconia, refresh the equipment platform (PrograMill 7), partner rather than build in scanning and printing, regionalise production through Local4Local (including a first Chinese plant from 2028), and invest in education and evidence. The constraint is scale: Ivoclar competes against listed peers three to four times its size with integrated implant and scanner ecosystems, and its CHF cost base amplifies every currency move.
Net assessment: a stable, strategically well-positioned but low-growth specialist in transition, with execution on zirconia, China and cost efficiency as the decisive variables.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Born | Joined | In corporate management since | Prior roles / notes |
|---|---|---|---|---|---|
Markus Heinz | Chief Executive Officer | 1,969 | 1985 | 2015 (CEO since 2023) | 1985 to 2011 Ivoclar Manufacturing Naturns (Italy); 2011 to 2015 MD Naturns; later Group COO; background in production, supply chain, organisational development |
Michael Bickel | Chief Financial Officer | 1,971 | 2023 | 2023 | Finance and operations executive with global experience; succeeded Franz Berger (CFO 2012 to mid-2024) |
Martin Frontull | Chief Marketing Officer | 1,987 | 2009 | 2025 | Previously Managing Director Germany (Ellwangen) until July 2025 |
Dr Thomas Hirt | Chief Technology Officer | 1,967 | 2010 | 2013 | Leads R&D |
Chester Spivey | Chief Commercial Officer North America | 1,965 | 1998 | 2025 | Long-tenured North America executive |
Mirco Stiehle | Chief Commercial Officer LATAM & APAC | 1,971 | 2019 | 2024 | Head of LATAM from Dec 2019; prior roles in medical device/dental industry in Germany, Japan and the US |
Stefan Riegler | Chief Production Officer | 1,981 | 1997 | 2025 | Spokesperson for Local4Local / Shanghai project |
Executive Leadership Team — Dr Karen J. Huebscher
| Name | Role | Background (public sources) |
|---|---|---|
Dr Karen J. Huebscher | President of the Supervisory Board | PhD (ETH Zurich), MBA (IMD); Vice Chair of Sandoz Group AG (since 2023); former CEO of Solvias (2014 to 2021); former Tecan board member; long Novartis career (investor relations, Vaccines & Diagnostics executive committee, M&A); founder of FibulaMedical (2012) |
Christina Zeller | Vice President of the Supervisory Board | Owner-family representative; joined board 2019; led CSR efforts |
Dr Friederike Hoffmann-Sieg | Member | Digitalisation expertise; joined 1 Sep 2022 |
Prof Dr Peter Leibfried | Member | Academic (accounting/finance profile) |
Prof Dr-Ing Wolfgang Reitzle | Member | Former Linde CEO and chairman; former Continental chairman |
Governance Overview
| Feature | Status |
|---|---|
Chair/CEO separation | Yes; non-executive Supervisory Board chaired by an external professional |
Board independence | Majority external members (Huebscher, Hoffmann-Sieg, Leibfried, Reitzle); one family representative (Zeller) |
Gender | 3 of 5 board members are women (Huebscher, Zeller, Hoffmann-Sieg) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Jul 2019 | Gabathuler succeeds Ganley as CEO | Generational transition; Ganley to board |
Mar 2023 | Heinz succeeds Gabathuler | Gabathuler left to explore start-up/other options; Heinz mandated to focus on growth markets and core products |
Sep/Dec 2023 | Bickel named CFO; Stiehle to corporate management (from 1 Jan 2024) | Sales split into mature vs high-growth markets |
Jun 2024 | Franz Berger departs after 12 years as CFO | Planned handover |
1 Jul 2025 | Frontull becomes CMO (Heinz had led marketing on an interim basis); Süßmuth becomes MD Germany | Marketing leadership re-filled |
| 2025 | Spivey (CCO NA) and Riegler (CPO) join corporate management | Commercial and production focus |
Major Shareholders
| Holder | Stake |
|---|---|
Zeller family (descendants of Adolf Schneider) | Controlling / effectively 100% (exact stake not disclosed) |
Institutional holders | None (not listed) |
Competitive Landscape
Key Competitors
| Competitor | Ownership | Overlap with Ivoclar |
|---|---|---|
Dentsply Sirona | Listed (Nasdaq: XRAY) | Restoratives, CAD/CAM (CEREC), ceramics (Celtra), dentures, equipment |
Envista (Kerr, Nobel Biocare, Spark) | Listed (NYSE: NVST) | Composites, adhesives, cements, implants |
Straumann Group | Listed (SIX: STMN) | Digital/CAD-CAM, zirconia, implants; scanning |
Solventum (ex-3M Health Care; dental unit) | Listed (NYSE: SOLV) | Composites (Filtek), adhesives, cements, CAD/CAM blocks |
GC Corporation | Private (Japan) | Restoratives, ceramics (Initial), CAD/CAM blocks |
Kulzer (Mitsui Chemicals) | Subsidiary of listed parent | Composites, denture materials, lab |
VOCO | Private (Germany) | Composites, adhesives |
Kuraray Noritake Dental | Subsidiary of Kuraray (listed) | Adhesives (Clearfil), zirconia (Katana), ceramics |
VITA Zahnfabrik | Private (Germany) | Denture teeth, ceramics, furnaces |
Amann Girrbach | Private (Austria) | Lab CAD/CAM, zirconia, furnaces |
Zirkonzahn | Private (Italy) | Zirconia, mills |
Coltene | Listed (SIX: CLTN) | Restoratives, endo, infection control |
Shofu | Listed (Tokyo) | Restoratives, ceramics |
GC/other Asian makers, Upcera, Aidite (China) | Various | Low-cost zirconia, a pricing pressure source |
Peer Comparison FY2024
| Metric | Ivoclar (FY2023) | Straumann (FY2024, approx.) | Dentsply Sirona (FY2024, approx.) | Envista (FY2024, approx.) |
|---|---|---|---|---|
Revenue (approx.) | CHF 856M | approx. CHF 2.5bn | approx. USD 3.8bn | approx. USD 2.5bn |
Revenue growth | -1.8% reported CHF | Double-digit organic (approx.) | Approx. -4% reported | Approx. flat to slightly down |
Operating margin | — | Core EBIT approx. mid-20s % | Adjusted mid-to-high teens % | Adjusted low teens % |
R&D intensity | n/d (240+ R&D staff) | Approx. 5% | Approx. 4 to 5% | Approx. 5% |
Ownership | Private family | Listed | Listed | Listed |
Competitive Advantages & Vulnerabilities
| Advantages | Vulnerabilities |
|---|---|
IPS e.max brand and clinical evidence (more than 230M restorations; above 95% survival in company report) | Lithium disilicate patents mature; generic/low-cost lithium disilicate and zirconia from Asian makers; counterfeit products (company campaign Jul 2026) |
Installed base of Programat furnaces and validated workflows | Late in digital equipment vs Dentsply Sirona/3Shape; mill development delays cited in 2018 |
Education network (71 centres) and lab loyalty | Scale disadvantage vs USD 2.5 to 4bn peers |
Family ownership enables long-term investment | Opaque disclosure; no public capital-market access |
Diversified production (5 sites, China planned) | CHF cost base and translation exposure (explicitly cited in 2024) |
Open-partner model (3Shape, exocad, vhf, SprintRay) | Dependence on partners for scanning/printing; no implant business |
Recent Developments
Items not found in the period: guidance revisions, litigation, regulatory actions, additional layoffs, M&A, or published FY2024/FY2025 results.



